{"id":111183,"date":"2026-06-09T13:55:01","date_gmt":"2026-06-09T08:25:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=111183"},"modified":"2026-06-09T13:55:02","modified_gmt":"2026-06-09T08:25:02","slug":"divis-labs-pharma-stocks-wuxi-apptec-us-blacklist","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/divis-labs-pharma-stocks-wuxi-apptec-us-blacklist\/","title":{"rendered":"Divi’s Labs Share Price Jumps 3.33% on June 9, 2026 as Pentagon Blacklists WuXi AppTec, Opening CDMO Opportunity for Indian Pharma"},"content":{"rendered":"
<\/div>\n

Divi’s Labs share price +3.33% on Jun 9. Piramal Pharma +3.77%. Gland Pharma +2.68%. WuXi AppTec added to Pentagon Chinese military list. WuXi: 100kL peptide capacity, key GLP-1 supplier.<\/em><\/p>\n

The Divi’s Lab<\/a>s share price<\/strong> surged 3.33% on June 9, 2026, as investors rotated into Indian contract development and manufacturing organisations (CDMOs) following a landmark move by the United States Department of Defense, which added China’s WuXi AppTec to its official list of companies identified as Chinese military entities. The Pentagon’s action on WuXi AppTec creates immediate compliance and supply chain risk for American pharmaceutical innovators, particularly those relying on WuXi for GLP-1 peptide synthesis and active pharmaceutical ingredient supply, potentially redirecting significant business to Indian CDMO players led by Divi’s Laboratories, Piramal Pharma, and Gland Pharma.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n